Efzofitimod Granted Orphan Drug Status for Systemic Sclerosis
The Food and Drug Administration (FDA) has granted Orphan Drug designation to efzofitimod (ATYR1923) for the treatment of systemic sclerosis. Efzofitimod is a potential first-in-class selective modulator of neuropilin-2 that is designed to downregulate innate…